Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in polymer- and lipid-based non-viral drug delivery systems and their components. This includes the development and manufacturing of polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and advanced drug conjugation strategies. We support regulated biotech, pharmaceutical, and medical device programs from early development through GMP and commercial manufacturing.

Curapath offers a combination of off-the-shelf R&D and GMP-grade materials, as well as custom development services, enabling our partners to progress efficiently from early feasibility to scalable and regulatory-ready manufacturing. Our solutions include PEG alternatives, active targeting strategies for lipid nanoparticles (LNPs), and tunable transfection reagents, all designed with a strong focus on manufacturability, reproducibility, and long-term regulatory compliance, supporting both clinical and commercial supply of advanced delivery technologies.

Type of company:European Contract Development and Manufacturing Organization (CDMO)

Specialization:Non-viral drug delivery systems

Core technologies: Polymer and Lipid based delivery systems (LNPs,PNP,Polymer and Lipid excipients)

Capabliities : R&D, GMP manufacturing, commercial supply

Regulatory status: GMP certified, EMA inspected

Markets adressed:Oncology, cell and gene therapy, DNA and mRNA vaccines, medical devices, in vivo CAR-T programs and trasfection reagents

https://curapath.com/